✓Tender information last checkedLast checked 6 Oct 2026, 14:41.
Opportunity overview
In April 2015 the MOD signed a thirteen year contract with Leidos Europe Ltd to provide the procurement and inventory management of commodity items (as well as the storage and distribution services) historically provided in-house by the Logistic Commodities and Services Operating Centre. Leidos, working with the MOD, will transform the way these services are delivered to ensure requirements continue to be met whilst providing best value for money for the department. The organisation delivering these services is known as Team Leidos.
Team Leidos would like to make markets aware that we are intending to investigate innovative approaches to fill our Supply of Naloxone and Atropine requirements. We are interested in the following:
Atropine: Preferred product would be 2mg/mL in a 50mL vial, but the key requirement is the 100mg of drug in one vial.
Naloxone: Preferred product would be 2mg/mL in a 20mL vial. However, would accept 2mg/ml in 50ml vial (total dose of 100mg per vial).
It is the aim of this Preliminary Market Engagement Notice (PMEN) to encourage companies, suppliers, or manufacturers to make us aware and provide as much information as they are comfortable with, to help decide the future strategy for the range.
Team Leidos wishes to generate interest, information and views with other companies to understand the current market innovation and gain useful intelligence that can help our requirement.
To request the PMEN documents please contact:
Name and Email address
Macy Johnson
Macy.johnson248@teamleidos.mod.uk
In the email request the documents related the Supply of Naloxone and Atropine. The documents will then be sent for completion and should be returned to the same email addresses before the deadline. Responses are required as soon as possible to inform next steps, but the PMEN will remain open until 06/11/2026
Classification
CPV33000000 — Medical equipments, pharmaceuticals and personal care products
CPV33140000 — Medical consumables
CPV33600000 — Pharmaceutical products
Lots
Lot 1Value not stated
Documents and notices
Preliminary market engagement notice on Find a TenderOpen source ↗
Published notice details
Additional information from the published procurement release. Fields appear only when supplied by the source; check the original notice and tender documents before acting.
Medical equipments, pharmaceuticals and personal care products
Entry 2
Scheme
CPV
Id
33140000
Description
Medical consumables
Entry 3
Scheme
CPV
Id
33600000
Description
Pharmaceutical products
Delivery locations
Entry 1
Region
UK
Country
GB
Country Name
United Kingdom
Planning and budget
Milestones
Entry 1
Id
engagement
Type
engagement
Description
To request the PMEN documents please contact:
Name and Email address
Macy Johnson
Macy.johnson248@teamleidos.mod.uk
Request the documents related to the Supply of Naloxone and Atropine. The documents will then be sent for completion and should be returned to the same email addresses before the deadline. Responses are required as soon as possible to inform next steps, but the PMEN will remain open until 06/11/2026
Due
6 Nov 2026, 23:59
Status
scheduled
Documents
Entry 1
Id
094265-2026
Document Type
marketEngagementNotice
Notice Type
UK2
Description
Preliminary market engagement notice on Find a Tender
1 published notice version reviewed by ProcuraAxis.
1 VERSION
1
094265-2026Preliminary market engagement notice on Find a Tender ·
PROCURAAXIS ANALYSIS
ProcuraAxis Analysis
Our approved analysis of the opportunity appears below the official tender information.
ANALYSIS PREVIEW
Opportunity intelligence at a glance
Early-stage preliminary market engagement for the potential future supply of naloxone and atropine pharmaceutical products to Team Leidos/MOD. This is not an open tender. Suppliers/manufacturers are invited to request PMEN documents, provide market information and return completed responses by 6 November 2026.
Who this may suit
Relevant to pharmaceutical manufacturers, licensed wholesalers and suppliers able to offer atropine and naloxone vial presentations. Final supplier eligibility and tender requirements are unknown.
Key points identified
Atropine product requirementPreferred 2 mg/mL in a 50 mL vial; the key requirement is 100 mg of drug in one vial.Evidence: “Atropine: Preferred product would be 2mg/mL in a 50mL vial, but the key requirement is the 100mg of drug in one vial.”
Naloxone product requirementPreferred 2 mg/mL in a 20 mL vial; 2 mg/mL in a 50 mL vial, with 100 mg total dose per vial, is also acceptable.Evidence: “Naloxone: Preferred product would be 2mg/mL in a 20mL vial. However, would accept 2mg/ml in 50ml vial (total dose of 100mg per vial).”
Response contentProvide information that helps Team Leidos understand market innovation and inform its future strategy.Evidence: “provide as much information as they are comfortable with, to help decide the future strategy” and “understand the current market innovation and gain useful intelligence”.
94% approved-analysis confidence5 supplier criteria identified3 risks or unknowns
ProcuraAxis structures information found in published procurement records, checks the result for consistency and publishes only approved analysis. Confidence describes the completeness and consistency of the available source information; it is not a guarantee of eligibility or contract award.
Early-stage preliminary market engagement for the potential future supply of naloxone and atropine pharmaceutical products to Team Leidos/MOD. This is not an open tender. Suppliers/manufacturers are invited to request PMEN documents, provide market information and return completed responses by 6 November 2026.
Who this may suit
Relevant to pharmaceutical manufacturers, licensed wholesalers and suppliers able to offer atropine and naloxone vial presentations. Final supplier eligibility and tender requirements are unknown.
Key deliverables
Market information and completed PMEN response for atropine and naloxone supply
Atropine: preferred 2 mg/mL in a 50 mL vial; key requirement is 100 mg in one vial
Naloxone: preferred 2 mg/mL in a 20 mL vial; 2 mg/mL in a 50 mL vial is also acceptable
SUPPLIER REQUIREMENTS
5 criteria identified
Atropine product requirement
99% confidence
Preferred 2 mg/mL in a 50 mL vial; the key requirement is 100 mg of drug in one vial.
View supporting evidence
“Atropine: Preferred product would be 2mg/mL in a 50mL vial, but the key requirement is the 100mg of drug in one vial.”
Naloxone product requirement
99% confidence
Preferred 2 mg/mL in a 20 mL vial; 2 mg/mL in a 50 mL vial, with 100 mg total dose per vial, is also acceptable.
View supporting evidence
“Naloxone: Preferred product would be 2mg/mL in a 20mL vial. However, would accept 2mg/ml in 50ml vial (total dose of 100mg per vial).”
Response content
94% confidence
Provide information that helps Team Leidos understand market innovation and inform its future strategy.
View supporting evidence
“provide as much information as they are comfortable with, to help decide the future strategy” and “understand the current market innovation and gain useful intelligence”.
Eligible supplier types
97% confidence
Companies, suppliers or manufacturers are invited to participate in the market engagement.
View supporting evidence
“encourage companies, suppliers, or manufacturers to make us aware”.
Formal selection criteria
98% confidence
Unknown.
View supporting evidence
No formal supplier selection or qualification criteria are stated in the supplied notice.
COMMERCIAL AND DELIVERY
Contract intelligence
Commercial
Stated value
74% confidence
Up to GBP 400,000 is recorded for the opportunity; it is unclear whether this is an indicative future contract value or another notice-level estimate.
View supporting evidence
Opportunity record value_max: 400000 GBP.
Pricing and contract terms
98% confidence
Unknown.
View supporting evidence
The preliminary market engagement notice does not state pricing, contract duration, payment terms or final commercial model.
Delivery
Delivery geography
93% confidence
United Kingdom.
View supporting evidence
Delivery location is recorded as United Kingdom (region: UK).
Delivery timetable
99% confidence
Unknown.
View supporting evidence
No delivery start date, end date or schedule is stated.
PROCEDURE
How to respond
Procurement status
99% confidence
Upcoming early-stage preliminary market engagement; this is not an open tender.
View supporting evidence
Display status: upcoming; stage: planning; notice type: Preliminary market engagement notice on Find a Tender.
Engagement response deadline
98% confidence
6 November 2026.
View supporting evidence
“the PMEN will remain open until 06/11/2026”.
How to obtain PMEN documents
98% confidence
Email Macy Johnson at Macy.johnson248@teamleidos.mod.uk requesting documents relating to the Supply of Naloxone and Atropine; complete and return them to the same email address.
View supporting evidence
“To request the PMEN documents please contact... Macy.johnson248@teamleidos.mod.uk... The documents will then be sent for completion and should be returned to the same email addresses before the deadline.”
Future procurement route
98% confidence
Unknown.
View supporting evidence
The notice says the engagement will help decide the future strategy, but does not specify a future procurement procedure.
RISKS AND UNKNOWNS
Points requiring attention
Early-stage scope risk
99% confidence
The final scope, quantities, procurement route, commercial terms and tender timetable have not been defined.
View supporting evidence
This is a planning-stage PMEN intended to inform “future strategy”; no final tender documents are supplied.
Product naming discrepancy
98% confidence
The title uses “Nalaxone” while the description consistently refers to “Naloxone”; suppliers should confirm the intended product in any engagement response.
View supporting evidence
Title: “The Supply of Nalaxone and Atropine”; description: “Supply of Naloxone and Atropine”.
Response timing
96% confidence
The notice requests responses as soon as possible despite remaining open until 6 November 2026.
View supporting evidence
“Responses are required as soon as possible to inform next steps, but the PMEN will remain open until 06/11/2026”.
ProcuraAxis analysis supplements, but does not replace, the original notice and tender documents. Always verify eligibility, deadlines and commercial terms with the issuing authority.
Continue in your ProcuraAxis workspaceFree account · Full approved analysis